Combining chemical synthesis, biological testing, and mass spectrometry into a single integrated workflow could help researchers move more quickly against cancer drug targets.

Artificial intelligence (AI) is quickly becoming a key factor for life sciences companies. In addition to improving efficiency and ...

GCheck, a modern, compliance-first hire-to-retire screening platform and FCRA-regulated consumer reporting agency (CRA), ...

Explore how AI phenotypic screening transforms image-based drug discovery through advanced phenotypic data analysis and ML-driven cell-based assays.

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest ...

In this interview, AZoLife Sciences speaks with Boyd Butler, a microscopy and high-content screening expert at Molecular ...

Discover how automation, AI, and organoid technologies are improving drug discovery through scalable workflows.

New machine learning framework predicts promising nucleoside hydrogels before they are synthesized and tested in the ...

Discover why animal models fall short in AI drug discovery and how human-first datasets and functional genomics are changing ...

From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?

South Korean researchers have developed an automated, modular cell-free protein synthesis platform that slashes preparation ...